Azora Therapeutics reported its third quarter 2026 financial results, highlighting its recent transition to the Nasdaq under the ticker 'AZR' and the appointment of a new executive leadership team. The company remains on track to submit an IND and initiate a Phase 1a trial for its lead candidate AT177 in the first half of 2027.
“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis. We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist. We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora. Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.”
Matt Davidson, Ph.D., President, Co-Founder and Chief Executive Officer
Azora Therapeutics, Inc. (formerly Adial Pharmaceuticals) reported a significant net loss of $118.6 million for the nine months ended September 30, 2026, primarily driven by a $46.2 million charge for acquired in-process R&D and a $48.8 million change in the fair value of milestone warrant rights. Following its acquisition of Legacy Azora in June 2026, the company's cash position increased to $22.0 million, supported by $26.8 million in proceeds from a private placement of pre-funded warrants.
Azora Therapeutics appointed Aida Habtezion, M.D., Paul Hastings, and Thomas Soloway to its Board of Directors. The appointments include the reconstitution of the board's audit, compensation, and nominating committees, with Mr. Soloway serving as audit committee chair. All three new directors were determined to be independent under Nasdaq listing standards.
Adial Pharmaceuticals (renamed Azora Therapeutics) appointed Matthew Davidson, Ph.D. as President and CEO and Celia Economides as CFO, effective October 28, 2026. Dr. Davidson succeeds Cary J. Claiborne, whose employment was terminated. The leadership transition coincides with a corporate rebranding and a shift in focus toward advancing the company's ulcerative colitis candidate, AT177.
Adial Pharmaceuticals has further adjourned its 2026 Annual Meeting of Stockholders with respect to Proposals 3, 4, 5, and 6 until October 26, 2026. The delay is intended to provide additional time to obtain Nasdaq's conditional approval of an Initial Listing Application related to those specific proposals.
Adial Pharmaceuticals has further adjourned its 2026 Annual Meeting of Stockholders with respect to Proposals 3, 4, 5, and 6 until October 15, 2026. The delay is intended to provide additional time to obtain Nasdaq's approval of an Initial Listing Application related to those specific proposals. Votes already cast on these proposals remain valid, and the record date remains August 17, 2026.
Adial Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 17, 2026, where shareholders elected two Class II directors and approved several equity-related proposals. Key approvals included an amendment to the 2017 Equity Incentive Plan, the adoption of the new 2026 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan.